Pre-market hot trades in US stocks: SciSparc pre-market down 4.92%; VCI Global pre-market down 4.60%

Tracking Unusual Activity
2025.09.18 09:27
portai
I'm PortAI, I can summarize articles.

SciSparc pre-market down 4.92%; VCI Global pre-market down 4.60%; 89bio pre-market up 83.04%; Aptevo Therap pre-market up 82.27%; AquaBounty Technologies pre-market up 57.02%

Pre-market Hot Trades in US Stocks

SciSparc is down 4.92% in pre-market trading. According to recent key news:

  1. On September 17, AutoMax Motors filed a motion with the Jerusalem District Court to suspend the merger process with SciSparc. The court approved this motion due to uncertainties regarding AutoMax Motors meeting the merger conditions. This news caused SciSparc's stock price to surge 178% in pre-market trading, reaching $5.12.

  2. On September 16, SciSparc announced that AutoMax Motors submitted a motion to the Jerusalem District Court seeking approval for the merger agreement with SciSparc Merger Sub Ltd. The court approved this motion, suspending the process until September 30, 2025. This news led to a spike in SciSparc's stock price, which soared 89.13% in after-hours trading, reaching $3.48.

  3. On September 17, SciSparc's stock price significantly dropped from the announced merger price of $37.49. In contrast, the closing price on Tuesday was $1.84, and today's pre-market trading price is approximately $4.25. Today's news has resulted in heavy trading of SciSparc shares, with over 21 million shares changing hands as of the time of writing, compared to a three-month average daily trading volume of about 702,000 shares. Industry trends and macro dynamics have a significant impact.

VCI Global is down 4.60% in pre-market trading. According to recent important news:

  1. On September 17, VCI Global announced the cancellation of its previously announced plan to acquire a 20% stake in QuantGold Data Group Limited. This move aims to optimize the capital structure and is believed that the acquisition would not provide the best value for shareholders. This news led to a decline in stock price. Data source: GlobeNewswire. Industry trends are stable, and macroeconomic impacts are limited.

Top Gainers in Pre-market Trading of US Stocks

89bio is up 83.04% in pre-market trading. According to recent important news:

  1. On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This news significantly boosted 89bio's stock price. Data source: Zhitong Finance.

  2. On September 18, 89bio's key drug pegozafermin is in late-stage development and is expected to become the best treatment for MASH. This news has strengthened market confidence in 89bio's future growth. Data source: Zhitong Finance.

  3. On September 18, Wall Street gave 89bio stock a strong buy rating with a target price of $27, indicating a potential upside of 234.16%. This rating further propelled the stock price increase. Data source: TipRanks. The biopharmaceutical industry is active in mergers and acquisitions Aptevo Therapeutics pre-market rose 82.27%. Based on recent key news:

  4. On September 16, Aptevo Therapeutics announced that the third cohort of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate, leading to a 57% increase in stock price. The study tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients.

  5. On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months, indicating a strong market reaction to the news.

  6. On September 17, despite facing challenges in financial performance, Aptevo's positive progress in its oncology pipeline provides potential upside. The biotechnology industry is highly volatile and requires caution.

AquaBounty Technologies pre-market rose 57.02%. Based on recent important news:

  1. On September 18, technical analysis of AquaBounty Technologies showed a neutral outlook, with mixed momentum indicator signals. The negative price-to-earnings ratio and lack of dividends further affected the stock's attractiveness. Improvements in operational efficiency and cash flow management are crucial for enhancing its financial health. This analysis led to increased market attention on the stock, driving up its price. Data source: Spark report. The biotechnology industry has shown recent volatility
Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.